WallStSmart

MiMedx Group Inc (MDXG)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiMedx Group Inc generates 47767% more annual revenue ($355.17M vs $742,000). MDXG leads profitability with a 1.8% profit margin vs 0.0%. MDXG earns a higher WallStSmart Score of 43/100 (D).

MDXG

Hold

43

out of 100

Grade: D

Growth: 6.7Profit: 3.5Value: 4.7Quality: 8.5
Piotroski: 3/9Altman Z: 4.24

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDXGUndervalued (+87.6%)

Margin of Safety

+87.6%

Fair Value

$41.87

Current Price

$4.57

$37.30 discount

UndervaluedFair: $41.87Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDXG3 strengths · Avg: 10.0/10
EPS GrowthGrowth
99.5%10/10

Earnings expanding 99.5% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.2410/10

Safe zone — low bankruptcy risk

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

MDXG4 concerns · Avg: 3.0/10
Market CapQuality
$671.30M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

Profit MarginProfitability
1.8%3/10

1.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDXG

The strongest argument for MDXG centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MDXG

The primary concerns for MDXG are Market Cap, Return on Equity, Profit Margin. A P/E of 115.0x leaves little room for execution misses. Thin 1.8% margins leave little buffer for downturns.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

MDXG carries more volatility with a beta of 1.42 — expect wider price swings.

MDXG is growing revenue faster at -34.7% — sustainability is the question.

MDXG generates stronger free cash flow (-11M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDXG scores higher overall (43/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiMedx Group Inc

HEALTHCARE · BIOTECHNOLOGY · USA

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?